Ping An Bio

Ping An Biopharma is a biotechnology company based in Shanghai and a subsidiary of the Ping An Insurance (Group) Company of China. The company focuses on the research and development of biologics, particularly biosimilars and innovative monoclonal antibodies targeting oncology and autoimmune diseases. Its pipeline includes several late-stage candidates, such as biosimilars for bevacizumab and adalimumab, aimed at providing high-quality, affordable therapeutic options for the Chinese market. Ping An Biopharma leverages the extensive healthcare and insurance ecosystem of its parent company to integrate drug development with patient management services. The firm plays a strategic role in Ping An's broader vision of combining finance with healthcare by expanding the group's capabilities into the biopharmaceutical sector.